## **Special Issue**

# Anti-Cancer Drug: Discovery, Development and Combination

## Message from the Guest Editor

Cancer is recognized as a multifactorial disease and its progression is regulated by extremely complex mechanisms. Furthermore, the contribution of such carcinogenic factors to malignant behavior is dependent on the type of cancer and the stage of the disease.

Armed with this knowledge, researchers have discovered many promising candidates for cancer therapy, and some are now being tested in clinical trials. Various new therapeutic targets, including chemical compounds and natural products, have been identified from basic and translational studies.

The aim of this Special Issue is to collect research papers, reviews, and communications focused on the discovery and development of anti-cancer drugs, as well as potential therapeutic targets, for various types of cancers. Moreover, clinical and translational studies on anti-cancer drugs used to improve the efficacy of conservative therapies, to decrease the number of residual cancer cells after operation, and to maintain the quality of life in patients with cancer, are invited.

## **Guest Editor**

Dr. Yasuyoshi Miyata

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

### Deadline for manuscript submissions

closed (31 March 2020)



# Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/26149

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/ molecules





## **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

#### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

## Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

